Advertisement

Annals of Hematology

, Volume 96, Issue 4, pp 707–708 | Cite as

Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia

  • Xueya Zhang
  • Jingxin PanEmail author
Letter to the Editor

Dear Editor,

Acute promyelocytic leukemia (APL) is characterized by the reciprocal chromosomal translocation t(15;17)(q22;q21), leading to a fusion of the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor-a gene (RARA) on chromosome 17. Two drugs in clinical use for APL, arsenic trioxide (ATO), and all-trans retinoic acid (ATRA), both act by promoting degradation of PML-RARA. When used as a combination therapy, these drugs lead to durable remission of APL and make it is a highly curable disease [1].

Recently, two randomized trials conducted by Lo-Coco F et al. and Zhu HH et al. provided strong evidence supporting the use of ATO and ATRA as front-line for APL [1, 2]. However, as ATO and ATRA therapy are more and more widely adopted in treatment for APL, acquired resistance to ATO and ATRA therapy has been recognized in clinical practice.

The C212/213S mutant of the PML, which is thought to be critical for ATO binding, has been described by Jeanne M et al....

Keywords

Retinoic Acid Acute Promyelocytic Leukemia Arsenic Trioxide Acute Promyelocytic Leukemia Cell Acute Promyelocytic Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This research work was supported in part by a grant from the Scientific Research Foundation of The Second Hospital of Fujian Medical University, Fujian Province (2012MP13).

References

  1. 1.
    Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker UL-Coco F, Avvisati G, Vignetti M (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121CrossRefPubMedGoogle Scholar
  2. 2.
    Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ (2013) Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 31:4215–4221CrossRefPubMedGoogle Scholar
  3. 3.
    Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, de Thé H (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18:88–98CrossRefPubMedGoogle Scholar
  4. 4.
    Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T (2011) Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood 118:1600–1609CrossRefPubMedGoogle Scholar
  5. 5.
    Zhu HH, Qin YZ, Huang XJ (2014) Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med 370:1864–1866CrossRefPubMedGoogle Scholar
  6. 6.
    Lehmann-Che J, Bally C, de Thé H (2014) Resistance to therapy in acute promyelocytic leukemia. N Engl J Med 371:1170–1172CrossRefPubMedGoogle Scholar
  7. 7.
    Jing Y, Xia L, Waxman S (2002) Targeted removal of PML-RARα protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 100:1008–1013CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of HematologyThe Second Affiliated Hospital of Fujian Medical UniversityQuanzhouChina

Personalised recommendations